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Introduction: Previous studies have produced controversial results regarding whether mesenchymal stem cells
(MSCs) promote or inhibit tumor development. Given the dual role of MSCs in inflammation and cancer, in this
study the colitis-associated colorectal cancer (CAC) model was used to examine whether umbilical cord tissue-derived
MSCs could prevent neoplasm by inhibiting chronic inflammation.
Methods: MSCs were obtained and identified using flow cytometry. Colitis-associated colorectal cancer model was
induced using azoxymethane (AOM) and dextran sulfate sodium (DSS) and MSCs were injected intravenously twice.
Levels of immune cells in mesenteric lymph node including regulatory T (Treg) cells were detected using flow cytometry.
Naïve T cells and Jurkat cells were co-cultured with MSCs and the effect of MSCs on Treg cells differentiation was evaluated.
Results: After injection through tail vein, MSCs could migrate to colon and suppress colitis-related neoplasm. This tumor
suppressive effect was characterized by longer colon length, decreased tumor numbers and decreased expression of
Ki-67. Moreover, MSCs alleviated the pathology of inflammation in the colitis stage of CAC model and inhibited
inflammation cytokines both in colon and serum. Furthermore, Treg cells were accumulated in mesenteric lymph
node of MSCs-treated mice while the percentage of T helper cells 2 (Th2) and Th17 were not changed. Of note,
MSCs secreted transforming growth factor-β (TGF-β) enhanced the induction of Treg cells from naïve T cells. The
conditioned medium of MSCs also activated Smad2 signaling, which has been reported to regulate Treg cells.
Conclusions: These results proved that MSCs could migrate to colon tissues and induce the differentiation of
Treg cells via Smad2 as so to inhibit the colitis and suppress the development of CAC.Introduction
The connection between inflammation and tumor devel-
opment was noticed after Virchow demonstrated that
cancer tended to occur at a site of chronic inflammation
[1]. Colorectal cancer which includes hereditary, spor-
adic and colitis-associated colorectal cancer (CAC) is
one of the most common malignancies. More and more
evidence shows that chronic inflammation of the colon
is an important factor for the progression of colorectal
cancer [2]. Patients with inflammatory bowel disease
(IBD), such as Crohn’s disease and ulcerative colitis,
have a higher risk of colorectal cancer development than
the healthy population. It is now becoming clear that
tumor microenvironment, which is largely orchestrated* Correspondence: yayihou@nju.edu.cn; wangtt@nju.edu.cn
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unless otherwise stated.by inflammatory cells, is an indispensable participant in
the neoplastic process, including cancer cell prolifera-
tion, survival and migration [3]. These insights are fos-
tering new anti-inflammatory therapeutic approaches to
cancer [4].
Mesenchymal stem cells (MSCs), which are derived
from a variety of tissues and have a fibroblast-like
morphology, have the capability of self-renewal and dif-
ferentiation. MSCs can migrate to the site of tissue dam-
age induced by inflammation and play an anti-
inflammatory role through regulation of the function of
dendritic cells, natural killer cells (NK cells), T cells, and
B cells [5]. MSC can also induce regulatory T (Treg) cells
and maintain the capability of Treg cells [6-8]. These
properties, which are useful for therapeutic purposes, have
recently been found to be abused by cancer cells for their
own end. In contrast, reports show that MSCs can inhibit
tumor growth under certain circumstances. Our previoushis is an Open Access article distributed under the terms of the Creative
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matory disorders in dextran sulfate sodium (DSS)-induced
colitis [9]. Given the dual role of MSCs in inflammation
and cancers, we hypothesized that MSCs may have an ef-
fect on the initiation and progression of CAC.
The role of the immune response in the formation of
CAC is complicated. Chronic colitis accompanied by a
large accumulation of T helper cell 1 (Th1), Th2 and
Th17 promotes neoplastic risk, whereas excessive im-
munosuppression regulated by Treg cells enhances the
survival of tumor cells [1,10,11]. Many researchers have
reported that excessive Th1 cells in intestinal mucosa
are the main reason for chronic colitis; these cells pro-
duce interferon (IFN)-γ and interleukin-2 (IL-2) [12,13].
Meanwhile, CAC was also characterized as a Th2/Th17
disease accompanied by overproduction of cytokines
such as IL-4, IL-5, IL-13 and IL-17 [14,15]. Importantly,
Treg cells, which are important in regulating immune
responses by selectively suppressing effector T cells, are
believed to play an important role in gut homeostasis
and limiting intestinal inflammation [16-18].
Given the dual regulatory effect of MSCs, we hypothe-
sized that MSCs, which modulate immune cells including
Treg cells, may have effective anti-inflammation effects on
colitis and eventually suppress CAC. To test this hypoth-
esis, MSCs were obtained and injected intravenously in
CAC mouse. The therapeutic effects of MSCs on both in-
flammation and tumor stage of CAC were investigated.
Methods
Mice and CAC model
The CAC model was induced in C57BL/6 male mice (eight
weeks of age) purchased from the Model Animal Research
Center of Nanjing University. All of the animals received
care according to the Guide for the Care and Use of Labora-
tory Animals. The protocol was approved by the Committee
on the Ethics of Animal Experiments of Nanjing University
Medical School. Mice were divided into four groups: normal
group untreated with MSCs (n = 12); normal group treated
with MSCs (n = 12); tumor group untreated with MSCs
(n = 16); and tumor group treated with MSCs (n = 16).
After treatment with intraperitoneal azoxymethane
(AOM) (10 mg/kg, 13.4 M, purity ≥98%; SIGMA,
Aldrich, St. Louis MO, USA), three cycles of 2% (w/v)
DSS (40,000 Da; SIGMA, Aldrich, St. Louis MO, USA)
in the drinking water (7 days DSS and 14 days water) in-
duced long-lasting chronic DSS colitis in these mice, as
previously described [19]. Mice were checked daily for
behavior. At day 5 and day 26, mice were intravenously
injected with 2 × 105 MSCs diluted in 200 μl phosphate-
buffered saline (PBS) or a vehicle control (PBS alone)
through the tail vein. The mortality rate of this animal
model is 0% to 5%. Half of the mice in each group were
sacrificed at day 33 to investigate the progression ofinflammation, and the others were sacrificed at day 70
to evaluate the development of tumor. The degree of
colitis was evaluated daily by scoring the clinical disease
activity (0 to 4), which includes stool status, fecal blood
and weight loss. Colons removed from cecum to anus
were collected, photos were taken, and the colons pre-
pared for histopathological analysis, immunohistoche-
mistry and quantitative real-time PCR (Q-PCR) analysis.
Preparation of umbilical cord-derived MSCs
Human umbilical cords were obtained from the Affiliated
Drum Tower Hospital of Nanjing University Medical School.
The Drum Tower Hospital ethics committee approved the
consent forms and the protocol for evaluation of the tissue
and patients gave written consent. The umbilical cords were
rinsed with PBS in penicillin and streptomycin, and then the
umbilical arteries and veins were removed. The remaining
tissue was cut into 1 to 2 mm pieces and floated in (Dulbec-
co’s) modified Eagle’s medium/nutrient F-12 Ham’s (Gibco,
Grand Island, NY, USA). The pieces were subsequently
digested in an enzyme cocktail (hyaluronidase 5U/ml, colla-
genase 125U/ml, and dispase 50U/ml; SIGMA) for three
hours at 37°C. After this tissue was crushed with forceps and
large pieces were removed, human umbilical cord MSCs
were harvested and plated into a culture flask. The cells were
incubated at 37°C in an incubator with 5% CO2 at saturating
humidity. When cells developed colonies and reached 70%
to 80% confluence, the cells were detached with 0.25%
trypsin-ethylenediaminetetraacetic acid (EDTA) and pas-
saged to a culture flask for further expansion.
Determination of MSC migration
MSCs migrating to the intestines in vivo were detected by
labeling with the fluorescent dye CM-DiI (Molecular Probes
Eugene, Oregon, USA). Before being injected, MSCs were
resuspended in PBS containing 2 μg CM-DiI, and then incu-
bated at 37°C for five minutes followed by fifteen minutes at
4°C in the dark. Cells were washed twice with PBS and re-
suspended to be injected in the tail vein. Mice were killed
(at day 8 and day 12) and tissues were collected to make
paraffin sections. MSCs were determined by fluorescence
microscope detection of CM-DiI dye (red).
Histopathological analysis
For histopathological examination, intestinal tissue was em-
bedded in paraffin, sectioned and stained with hematoxylin
and eosin (H & E). Inflammation was blindly scored from 0
to 4 as follows: 0, no signs of inflammation; 1, low
leukocyte infiltration; 2, moderate leukocyte infiltration; 3,
high leukocyte infiltration, moderate fibrosis, high vascular
density, thickening of the colon wall, moderate goblet cell
loss, and focal loss of crypts; and 4, transmural infiltration,
massive loss of goblet cells, extensive fibrosis, and diffuse
loss of crypts.
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Paraffin-embedded intestinal sections were mounted on
slides, dewaxed in xylene, and rehydrated in graded alcohol
washes. Slides were heated by microwave in 0.01 mol/L tri-
sodium citrate buffer for antigen retrieval. Bovine serum al-
bumin, 5%, (BSA) was used to block nonspecific bonding
sites for 30 minutes and 3% H2O2 was used to suppress en-
dogenous peroxidase activity. Slides were then incubated
with primary antibody (Ki-67, p-P65 and FoxP3) overnight
at 4°C and washed with Tris-buffered saline (TBS) before
incubation with labeled polymer horseradish peroxidase
rabbit antibody for 30 minutes. Counterstaining was per-
formed with hematoxylin. Slides were dehydrated through
ascending alcohols to xylene and mounted to take photos.
The proliferation index of Ki-67 and p-P65 was given as
the ratio between positive nuclei and total number of nu-
clei per crypt. Five visual fields per sample were selected
randomly to analyze at least 20 crypts.
mRNA isolation and quantitative-PCR
Total RNA was extracted from intestinal tissue with TRIzol
Reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. A total of 1 μg RNA was used
as the template for single strand cDNA synthesis. Quanti-
tative PCR (Q-PCR) for GAPDH, IL-1β, IL-6 and TNF-α
was performed on an Applied Biosystems 7300 Sequence
Detection System (Applied Biosystems, Foster city CA,
USA) using SYBR green dye (Invitrogen, USA), pro-
grammed for 95°C for 10 minutes, then 40 cycles of 95°
C for 15 seconds, 60°C for 30 seconds, and 72°C for 30
seconds. All reactions were run in triplicate.
Cytokine analysis by Bio-Plex Assay
IL-α, IL-β, IL-3, IL-4, IL-5, IL-6, IL-12, IL-13, G-CSF
and RANTES in sera were quantitated to investigate the
change in the immune system using the 10-plex Bio-Rad
(Bio-Rad, Hercules CA, USA), according to the manu-
facturer’s instructions.
T cell preparation and treatment
CD4+CD62L+ T cells were positively selected from mur-
ine splenocytes using a magnetic-activated cell-sorting
system (Miltenyi Biotec, Bergisch Gladbach Germany).
High purity naive T cells were plated into 12-well
culture plates and cultured in Roswell Park Memorial
Institute (RPMI) 1640 (Gibco, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS) and ant-CD3/
CD28 (eBioscience, San Diego, CA, USA) monoclonal
antibodies. Then MSCs were added in the top chamber
of 12-well transwell chambers with 3-μm pore polycar-
bonate filters and co-cultured with naive T cells at 37°C
in an incubator with 5% CO2 at saturating humidity.
Transforming growth factor-β1 (TGF-β1) (Miltenyi
Biotec Bergisch Gladbach, Germany) and anti-TGF-β1antibody (ab64715, Abcam, USA) was also added in the
same chamber to evaluate the effect of MSCs on the dif-
ferentiation of naive T cells. Overall, we had four
groups: CD4+T cells alone, CD4+T cells cultured with
TGF-β, CD4+T cells cultured with MSCs, and CD4+T
cells cultured with anti-TGF-β/MSCs. Cells at the bot-
tom of the chamber were collected and analyzed.
Flow cytometric analysis
Cells were stained with CD29, CD44, CD73, CD90,
CD105, HLA-ABC, CD14, CD31, CD34, CD45, HLA-
DR, CD3, CD4, CD8, CD25, IL-4, IL-17, and FoxP3
(eBioscience). In addition, intracellular IL-4, IL-17 and
FoxP3 staining were treated with a FoxP3 staining buffer
set (eBioscience). Flow cytometry was carried out on the
FACScalibur flow cytometer (BD, San Diego, USA). Data
were analyzed using FlowJo software (Treestar, Inc., San
Carlos, CA, USA).
Western blots
Jurkat cells, which were stimulated by MSCs condi-
tioned medium, were lysed in a buffer containing 50
mM Tris-Cl pH 8.0, 150 mM NaCl, 0.02% NaN3, 0.1%
SDS, 100 mg/ml phenyl-methylsufonyl fluoride (PMSF),
1 mg/ml aprotinin, 1% Triton. A total of 10 μg/mL
aprotinin, 10 μg/mL leupeptin, 1 mM dithiothreitol, 1
mM paranitrophenyl phosphate, and 0.1 mM Na3VO4
were added as protease and phosphatase inhibitors.
After centrifugation, protein samples were subjected to
10% SDS-PAGE and transferred onto polyvinylidene
difluoride (PVDF) membranes (Roche, Mannheim,
Germany). The membranes were blocked in TBST (1
mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20)
containing 5% BSA for 0.5 hour and subsequently incu-
bated overnight at 4°C with diluted primary antibodies
against GAPDH, Smad2 and Phospho-Smad2. The band
was quantified using the FluorChem FC2 system (Alpha
Innotech Corporation St. Leonardo, CA, USA).
Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM). Student’s t-test was used to compare be-
tween two groups. One-way analysis of variance
(ANOVA) was used to compare among three or more
groups. A P value of <0.05 was considered significant,
and survival curves were performed with GraphPad
Prism software (San Diego, CA, USA).
Results
MSCs migrate to the colon and decrease the incidence of
colitis-related neoplasm
MSCs were isolated from human umbilical cord tissue
and confirmed by analyzing MSC-related cell surface
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MSCs were successfully obtained with positive markers
of CD29, CD44, CD73, CD90, CD105 and HLA-ABC,
and with negative markers of CD14, CD31, CD34, CD45
and HLA-DR. We then detected the migration activity
of MSCs in mice through tail vein injection. Compared
with liver, more accumulation of MSCs was found in
lung for three days after injection in normal mice. In the
tumor group, that is, the mice treated with AOM and
2% DSS, the amount of MSCs in lung was decreased
(Figure 1B). At the same time, MSCs were also detected
in colon (Figure 1C). These results indicated that MSCs
were sufficiently dynamic to migrate in vivo and could
migrate to colon tissues when the intestinal epithelia of
mice were damaged by DSS. At day 12, MSCs still were
found in the colon tissue (Figure 1D), suggesting that
this time interval provided a potential therapeutic
chance of MSCs in colon tissues.Figure 1 The phenotype and migration pathway of MSCs in the DSS/AOM
FACScalibur flow cytometer. (B) Liver and lung in each group were moved
pathway of MSCs stained with CM-DiI (red). (C) and (D) show colon tissue co
AOM, azomethane; DSS, dextran sulfate sodium; FACS, fluorescence activatedThe CAC model was successfully induced by injecting
mice with AOM and 2% DSS (Figure 2A). Mice in the
tumor group developed colon tumors mainly in the distal to
middle colon, which is the predominant localization of hu-
man colorectal tumors. We noticed that mice treated with
MSCs had fewer macroscopic tumors (Figure 2B and C)
and longer colon length (Figures 2E). The average size of
the tumor was not affected in the two groups (Figure 2D).
Moreover, immunohistochemical analysis showed that
Ki-67 was lower in colon tissues of mice treated with
MSCs than in those without treatment (Figure 2F and
G). These data confirmed that MSCs could inhibit
tumor development in the CAC model.
MSCs alleviate the pathology of DSS-induced chronic colitis
To induce colorectal cancer successfully, the chronic
colitis should emerge first in three cycle inductions. It is
now commonly accepted that inflammation contributes-induced model. (A) Expression of MSC phenotype was detected by
, collected and paraffin sections made at day 6 to detect the migration
llected to detect the migration pathway of MSCs at day 6 and day 10.
cell sorting; MSCs, mesenchymal stem cells.
Figure 2 MSCs decrease tumor incidence on day 70. (A) After AOM injection, animals were subjected to three cycles of DSS. MSCs (2 × 105) were
injected at day 4 and day 25. Animals were sacrificed at day 33 and day 70. Colons were excised for macroscopic observation (B) and tumor
numbers (C), tumor size (D) and colon length were assessed (E). The expression of Ki-67 (F and G) in the treated and untreated colons was
examined by immunohistochemistry staining. Values are expressed as means ± SEM. *P <0.05, or **P <0.01. AOM, azomethane; DSS, dextran sulfate
sodium; MSCs, mesenchymal stem cells; SEM, standard error of the mean.
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development. To confirm that MSCs inhibit carcinogen-
esis through inhibition of colonic inflammation, half of
the mice in the tumor group were sacrificed on day 32.
As shown in Figures 3A to D, MSC treatment signifi-
cantly alleviated chronic inflammation with improved
clinical scores. MSC treatment also improved colitis
characteristics with increased body weight (P <0.05) and
colon length (P <0.05). Moreover, histological examin-
ation of the colon in mice without MSCs showed patchy
ulceration, epithelial cell loss, reduction of the density of
tubular glands, focal loss of crypts, inflammatory cellinfiltrates and transmural inflammation involving all
layers of the bowel wall. Expectedly, these colitis charac-
teristics were reversed after MSC treatment (Figures 3E
and F, P <0.05). These results consistently demonstrated
that during the development of CAC, MSCs had a pro-
tective function on DSS-induced colitis by inhibiting ex-
cessive inflammation in colon tissues.
MSCs inhibit inflammatory cytokines in colon and serum
Cytokine levels are critical evidence to show the effect of
immune cells on CAC growth. In order to test the effect
of MSCs on levels of inflammatory cytokines, serum
Figure 3 MSCs protect mice against the development of DSS-induced colitis on day 33. Colons were excised for macroscopic observation (A)
and assessment of colonic length (B). (C) The changes in body weight were calculated based on initial body weight. (D) The clinical disease score
of colitis, which includes stool status, fecal blood, length of colon and weight loss, was used to evaluate the therapeutic effect of MSCs. (E) Colon
sections from mice with different treatments were examined using H & E staining. (F) Histology scores were derived from microscopic analysis of
longitudinal colon sections from each mouse. Values are expressed as means ± SEM. *P <0.05, or **P <0.01. DSS, dextran sulfate sodium; MSCs
mesenchymal stem cells; SEM, standard error of the mean.
Tang et al. Stem Cell Research & Therapy  (2015) 6:71 Page 6 of 11from different groups of mice was collected and cyto-
kine levels were detected using a Bio-Plex cytokine kit.
Compared with the untreated group, inflammatory cy-
tokines, including IL-1α, IL-1β, IL-5, IL-6 and IL-12,
were decreased significantly after treatment with MSCs
(Figure 4A, P <0.05).
Many DNA-binding proteins are aberrantly activated
in response to inflammatory stimuli, which can cause in-
appropriate induction of various proinflammatory genes
in tumor cells, tumor-associated stromal cells and sur-
rounding host tissues. NF-κB, one of these DNA-binding
proteins, has been identified as a potential molecular
bridge between inflammation and cancer, and can induce
proinflammatory cytokines such as IL-1, IL-6 and TNF-
α. mRNA in colon was extracted and gene expressions
of IL-1β, IL-6 and TNF-α were examined. As shown in
Figure 4B, the expressions of IL-1β, IL-6 and TNF-α
were reduced (P <0.05) after treatment with MSCs.Immunohistochemical analysis also showed that the pro-
tein level of p-P65 was decreased in colon tissues treated
with MSCs, compared with colon tissues without treat-
ment (Figure 4C).
Treg cells are up-regulated in the progression of chronic
colitis
To detect the regulatory effect of MSCs on immune
cells, flow cytometry was used to analyze changes of
adaptive immune cells in mesenteric lymph nodes after
treatment with MSCs for 33 days (colitis stage). As
shown in Figure 5A, the mean percentage of CD4+T
cells and CD8+T cells reflected no difference among
groups as well as Th2 and Th17 cells. As is well known,
forkhead box P3 (FoxP3) is the transcription factor of
Treg cells. Notably, CD4+CD25+FoxP3+ Treg cells were
significantly up-regulated by MSC treatment (Figure 5B,
P < 0.05). These phenomena suggest that MSC may just
Figure 4 MSCs suppressed the expression of inflammatory cytokines. (A) Bio-Plex Assay was used to analyze cytokine changes in mice plasma,
including IL-1α, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-12, IL-13, G-CSF and RANTES. (B) The expression levels of colonic inflammatory cytokines (IL-1β, IL-6
and TNF-α) from different groups were evaluated by Q-PCR. (C) The expression of p-P65 examined by immunohistochemistry staining comparing
the colons in the treated and untreated groups. Values are expressed as means ± SEM. *P <0.05, or **P <0.01. MSCs, mesenchymal stem cells;
SEM, standard error of the mean.
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Figure 5 The effect of MSCs on the accumulation of CD4+CD25+FoxP3+Treg cells. (A) Flow cytometry analysis of the mean percentage of CD4+T
cells and CD8+T cells in mesenteric lymph. (B) Flow cytometry analyzed the mean percentage of Th2, Th17 and Treg cells in mesenteric lymph.
Values are expressed as means ± SEM. *P <0.05. Colons collected at day 33 (C) and day 70 (D) stained with Foxp3 examined by immunohistochemistry.
MSCs, mesenchymal stem cells; SEM, standard error of the mean; Treg cells, regulatory T cells.
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lymph nodes to suppress excessive inflammation after
MSCs migrate to the colon. To further confirm the
involvement of Treg cells in intestinal inflammation,
FoxP3 stained by immunohistochemistry was used to
analyze whether Treg cells infiltrated to the stroma
and epithelia of the intestine. Interestingly, according
to the density of FoxP3, we found that Treg cells infil-
trated in intestinal stroma more in the MSC treated
group than in the untreated group (Figure 5C). We
also determined the density of Treg cells at day 70
(tumor stage). In contrast, the results showed that the
infiltrated Treg cells were found less in the MSCs
group compared to the neoplasm in the untreated
group (Figure 5D). Therefore, these results indicated
that MSCs indeed were involved in inducing Treg
cells to suppress colitis.MSCs increase Foxp3+ cells via activating Smad2
signaling in vitro
To explore how MSCs regulate Treg cells, naive CD4+T
cells were separated from mouse spleen and then stimu-
lated by anti-CD3/CD28 to maintain survival in vitro.
After co-culture with MSCs for two days, the expression
of FoxP3 slightly changed (Figure 6A). However, after
three days, the FoxP3+ cells were increased to 13.7% in
the TGF-β alone group and 20.2% in the MSC group. To
prove that the induction effect of MSCs is through TGF-
β, anti-TGF-β was added to the MSC supernatant. The
percentage of FoxP3+ cells returned to its normal level
in the anti-TGF-β group. Moreover, the MSC condi-
tioned medium was then used to stimulate Jurkat cells.
Mechanically, phosphorylation-Smad2 was activated
after 30 minutes treatment with MSCs while JNK and
p38 signaling showed no change (Figure 6B and C).
Figure 6 MSCs increase the expression of FoxP3 in naive CD4+T cells. (A) Naive CD4+T cells co-cultured with MSCs (ratio 1:5)/TGF-β (5 ng/ml) or
without MSCs/TGF-β in the presence of anti-CD3/CD28 (2 μg/ml each). T cells were harvested from different treatment groups to assess Foxp3
expression by flow cytometry. (B) MSCs conditioned medium was collected after 48 hours and 72 hours, and then used to stimulate Jurkat cells
for different times. were harvested to examine TGF-β signaling by Western blotting of Smad2 and phospho-Smad2. TCR signaling was examined
by Western blotting of JNK, phospho-JNK, p38 and phospho-p38. (C) The protein level of p-Smad2 was analyzed using Quantity One. Values are
expressed as means ± SEM. *P <0.05 or **P <0.01. MSCs, mesenchymal stem cells; SEM, standard error of the mean; TCR, T cell receptor; TGF-β,
transforming growth factor-β.
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creased the FoxP3+ cell populations via activating phos-
phorylation of Smad2.
Discussion
As it is difficult to cure tumors directly, many reports
have focused on anti-inflammation to inhibit the initi-
ation and progression of tumors [20]. Recently, some
studies have indicated that paeonol [20], glucosamine
[21], and digitoflavone [22] can significantly attenuate
inflammation and produce proinflammatory cytokines to
ameliorate CAC. Our previous research showed that
MSCs can regulate immunological balance [23-25] and
ameliorate DSS-induced acute colitis [9]. Based on these
studies, we designed this experiment to research
whether MSCs may inhibit tumorigenesis in the CAC
mice model. Our results found that MSCs could migrate
to the colon and suppress colitis-related neoplasms. This
tumor suppressive effect was characteristized by longer
colon length, decreased tumor numbers and decreased
expression of Ki-67. Furthermore, MSCs alleviated the
pathology of inflammation in the colitis stage of the
CAC model. Mechanically, Treg cells were accumulatedin mesenteric lymph node of MSC-treated mice. In vitro,
MSCs secreting TGF-β enhanced the induction of Treg
cells from naïve T cells.
The effect of MSCs on cancers is controversial. Many
studies have shown that MSCs can promote tumor
growth. B16 melanoma cells cannot form tumors in allo-
geneic mice unless co-injected with MSCs [26]. When
human breast cancer cells mixed with bone marrow-
derived human MSCs were injected in a mouse model,
there was a higher speed of metastases [27]. On the
other hand, there are also many reports proving that
MSCs can inhibit tumor growth. MSCs can exert an
anti-tumorigenic effect that is mediated by inhibition of
Akt activity in a model of Kaposi’s sarcoma [28]. MSCs
can also inhibit human liver cancer cell lines and the de-
velopment of a hepatoma model involving the wnt sig-
naling pathway [29]. However, there is much debate
about the function of MSCs in tumor development, and
it is difficult to research how MSCs suppress tumors dir-
ectly. In our CAC model, we found that MSCs could
suppress colitis at the colitis stage and eventually sup-
press tumor development at the tumor stage. Further-
more, inflammatory mediators were detected both in
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which had high levels in colitis [30], were significantly
decreased in the MSC treated group. These results to-
gether suggest that MSCs can play a therapeutic role in
the progression of CAC.
It is believed that Treg cells play an important role in
the regulation of colitis. Colitis induced by transferring
CD4+CD25RBhigh T cells into RAG−/− mice can be pre-
vented by CD4+CD25+ Treg cells [31]. Modulating the
balance between Treg and Th17 cells by IL-22 can also
reduce the pathological degree in experimental colitis
[32]. Here, we found that at the colitis stage, both the
colon and mesenteric lymph node had more infiltration
of Treg cells in MSC treated group than in the untreated
group. On the other hand, our results found that at the
tumor stage fewer Treg cells were infiltrated in the
MSCs treated group compared with the untreated group.
Here, we just injected MSCs twice to suppress inflam-
mation development at the colitis stage, so at the tumor
stage whether Treg cell infiltration could be affected by
MSCs needs further research.
FoxP3, which has been identified as the transcription
factor, is responsible for determining the function of
Treg cells. Various signals that induce the expression of
FOXP3 have been reported, such as T-cell receptor
(TCR), co-stimulatory molecules and cytokine receptors
[33]. IL-2 [34] and TGF-β [35] are essential cytokines for
the differentiation of CD4 + CD25 + FoxP3 + Treg cells
from naive CD4 + T cells. It has been reported that
MSCs can secrete TGF-β to interact with NK cells [36].
In vitro, we found that Treg cells were induced when
naive CD4 + T cells were co-cultured with MSCs and
then the TGF-β-Smad2 signal was also activated. All
these results support our hypothesis that MSCs may se-
crete TGF-β which was quantified in our previous study
[24] to induce Treg cells, and then suppress the progres-
sion of inflammation-dysplasia-carcinoma in CAC.
Conclusions
To sum up, our present research analyzed the function
of MSCs in CAC. We found that MSCs can inhibit col-
itis at the colitis stage and eventually suppress the devel-
opment of colon cancer at the tumor stage. The
expressions of inflammatory cytokines in blood and
colon tissue were all inhibited by MSCs. Importantly,
Treg cells accumulated in colon tissues following MSC
treatment. MSCs can raise the expression of FoxP3 in
naive CD4 + T cells and activate the TGF-β-Smad2 sig-
nal. Taken together, our results prove that MSCs can in-
duce Treg cells to suppress chronic inflammation and
then suppress the development of CAC.
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